HER2 Positive Breast Cancers Recruiting Phase 1 Trials for Trastuzumab (DB00072)

Also known as: HER2 Positive Breast Cancer

IndicationStatusPhase
DBCOND0066412 (HER2 Positive Breast Cancers)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02705859Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)Treatment